C Thongprayoon1, W Cheungpasitporn1, P Phatharacharukul2, P J Edmonds3, Q Kaewpoowat4, P Mahaparn5, J Bruminhent6, S B Erickson1. 1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. 2. Department of Internal Medicine, University of Minnesota, Minneapolis, MN, USA. 3. SUNY Upstate Medical University, Syracuse, NY, USA. 4. Division of Infectious Disease, University of Texas Medical School at Houston, Houston, TX, USA. 5. Division of Infectious Disease, Chulalongkorn University, Bangkok, Thailand. 6. Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Abstract
BACKGROUND: The objective of this systematic review and meta-analysis was to assess the clinical outcomes of Clostridium difficile infection (CDI) in patients with chronic kidney diseases (CKD) and end-stage renal disease (ESRD). METHODS: A literature search was performed from inception through February 2015. Studies that reported relative risks, odds ratios or hazard ratios comparing the clinical outcomes of CDI in patients with CKD or ESRD and those without CKD or ESRD were included. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using a random-effect, generic inverse variance method. RESULTS: Nineteen studies (a case-control and 18 cohort studies) with 116,875 patients assessing clinical outcomes of CDI were included in the meta-analysis. Pooled RR of severe or complicated CDI in CKD patients was 1.51 (95% CI: 1.00-2.28). The risk of recurrent CDI is significant higher in patients with a pooled RR of 2.73 (95% CI: 1.36-5.47). The pooled RR of mortality risk of CDI in patients with CKD, ESRD and CKD or ESRD were 1.76 (95% CI: 1.26-2.47), 1.58 (1.37-1.83) and 1.76 (1.32-2.34) respectively. CONCLUSION: This meta-analysis demonstrates poor outcomes of CDI including severe and recurrent CDI in CKD patients. History of CKD and ESRD are both associated with increased mortality risk in patients with CDI.
BACKGROUND: The objective of this systematic review and meta-analysis was to assess the clinical outcomes of Clostridium difficileinfection (CDI) in patients with chronic kidney diseases (CKD) and end-stage renal disease (ESRD). METHODS: A literature search was performed from inception through February 2015. Studies that reported relative risks, odds ratios or hazard ratios comparing the clinical outcomes of CDI in patients with CKD or ESRD and those without CKD or ESRD were included. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using a random-effect, generic inverse variance method. RESULTS: Nineteen studies (a case-control and 18 cohort studies) with 116,875 patients assessing clinical outcomes of CDI were included in the meta-analysis. Pooled RR of severe or complicated CDI in CKDpatients was 1.51 (95% CI: 1.00-2.28). The risk of recurrent CDI is significant higher in patients with a pooled RR of 2.73 (95% CI: 1.36-5.47). The pooled RR of mortality risk of CDI in patients with CKD, ESRD and CKD or ESRD were 1.76 (95% CI: 1.26-2.47), 1.58 (1.37-1.83) and 1.76 (1.32-2.34) respectively. CONCLUSION: This meta-analysis demonstrates poor outcomes of CDI including severe and recurrent CDI in CKDpatients. History of CKD and ESRD are both associated with increased mortality risk in patients with CDI.
Authors: A N Do; S K Fridkin; A Yechouron; S N Banerjee; G E Killgore; A M Bourgault; M Jolivet; W R Jarvis Journal: Clin Infect Dis Date: 1998-04 Impact factor: 9.079
Authors: Kathleen M Mullane; Oliver A Cornely; Derrick W Crook; Yoav Golan; Thomas J Louie; Mark A Miller; Michelle A Josephson; Sherwood L Gorbach Journal: Am J Nephrol Date: 2013-06-20 Impact factor: 3.754
Authors: Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox Journal: Clin Infect Dis Date: 2018-03-19 Impact factor: 9.079
Authors: Michael Kuniavsky; Keren Doenyas-Barak; Nethanel Goldschmidt; Amit Huppert; Olga Bronshtein; Chana Rosenfelder; Laurence S Freedman; Yaron Niv Journal: J Gen Intern Med Date: 2022-07-06 Impact factor: 6.473
Authors: Yoav Golan; Herbert L DuPont; Fernando Aldomiro; Erin H Jensen; Mary E Hanson; Mary Beth Dorr Journal: Open Forum Infect Dis Date: 2020-06-26 Impact factor: 3.835
Authors: Richard L Hengel; Timothy E Ritter; Ramesh V Nathan; Lucinda J Van Anglen; Claudia P Schroeder; Ryan J Dillon; Stephen W Marcella; Kevin W Garey Journal: Open Forum Infect Dis Date: 2020-03-19 Impact factor: 3.835